NCT06773936 2026-03-04
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Enrolling by invitation
Clinical Trials
17 trialsNCT07029776 2026-03-03
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Phase 2 Not yet recruiting
NCT07405736 2026-02-12
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06656598 2026-02-11
SPORADIC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT07372365 2026-01-28
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07199855 2025-09-30
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
Zhejiang University
Phase 2 Active not recruiting
NCT07014202 2025-07-30
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05827549 2025-06-06
ReCALL
Asan Medical Center
Phase 2 Recruiting
NCT05375708 2025-03-28
SIRIUS
UMC Utrecht
Phase 2 Suspended
NCT06744894 2024-12-20
SIL as Maintenance Therapy in Multiple Myeloma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT06503263 2024-09-19
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Navy General Hospital, Beijing
Phase 2 Recruiting
NCT06341556 2024-09-04
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Fudan University
Phase 2 Recruiting
NCT02396043 2023-06-18
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT03983226 2022-03-18
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT02919462 2018-01-16
HighTySy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT00580372 2016-09-20
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
University of Arkansas
Phase 2 Completed
NCT01665001 2012-08-17
Personalized Therapy of Precursor Lymphoid Neoplasms
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Phase 2 Unknown